Table 1 Demographic and clinical features of EBLs, NEBLs and NEBLs*

Age at symptom onset (years)

33.0±1.55

32.8±1.42

35.3±1.42

NS

NS

Sex(Male/Female)

2/14

7/46

4/33

NS

NS

Annualized relapse rate

2.11 ± 2.0

1.17 ± 0.6

1.10 ± 1.15

NS

NS

Relapse times

5(3–18)

5(2–16)

5(2–16)

NS

NS

Duration (months)

82.4±5.2

83.5±6.0

99.3±6.34

NS

NS

Brain symptom(%)

10(62.5%)

27(50.1%)

20(54.1%)

NS

NS

  encephalopathy symptom

6(37.5%)

3(5.6%)

3(8.1%)

0.004

0.016

  brain-stem symptom

5(31.2%)

20(37.7%)

13(35.1%)

NS

NS

  cerebellum involvement

2(12.5%)

4(7.5%)

3(8.1%)

NS

NS

  homonymous hemianopia

3(18.8%)

0(0)

0(0)

0.011

0.024

EDSS*

2.49 ± 1.03

1.98± 0.97

2.00 ± 1.04

NS

NS

EDSS**

7.67 ± 1.48

5.32 ± 1.82

5.32 ± 1.82

0.000

0.000

Serum Analysis

 CRP (mg/l)

12.32 ± 3.05

2.65 ± 0.61

3.01 ± 1.01

0.000

0.000

 ESR (mm/H)

27.67 ± 16.49

15.83 ± 11.28

15.24 ± 12.24

0.005

0.004

 C3 (g/l)

1.42 ± 0.50

1.15 ± 0.27

1.14 ± 0.30

0.049

0.043

 C4 (g/l)

0.29 ± 0.16

0.22 ± 0.09

0.22 ± 0.07

0.046

NS

 CH50 (U/ml)

50.73 ± 10.62

45.96 ± 11.32

44.43 ± 11.52

NS

NS

 AQP4 seropositivity

16(100%)

37(69.8%)

37(100%)

0.008

CSF Analysis

 CSF-TP (mg/ml)

0.41 ± 0.25

0.29 ± 0.17

0.31 ± 0.18

NS

NS

 CSF-WBC (10)

6.0(0–58)

5(0–98)

5(0–46)

NS

NS

 CSF-OCB

1(6.25%)

3(5.66%)

2(5.40%)

NS

NS